Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell S von Itzstein

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Clinical Chemistry|February 28, 2024
Resistance Mechanisms in ROS1-Positive Lung Cancer: New Insight into a Rare but Clinically Important EntityMitchell S von Itzstein, David E Gerber
Translational Lung Cancer Research|March 11, 2026
A new therapeutic approach to <i>KRAS</i> mutant non-small cell lung cancer: the emerging role of exportin 1 inhibitionMitchell S von Itzstein, David E Gerber
Clinical Chemistry|May 5, 2020
Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and DiagnosisMitchell S von Itzstein, Shaheen Khan, David E Gerber
Ebiomedicine|September 25, 2020
Do mRNA profiles of lung adenocarcinomas provide information that will help individual patients?Mitchell S von Itzstein, David E Gerber, John D Minna
Journal of Medical Case Reports|July 24, 2022
Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case reportAmrit S Gonugunta, Mitchell S von Itzstein, David E Gerber
Translational Lung Cancer Research|September 12, 2022
Circulating mitochondrial DNA as a biomarker for lung cancer screeningMitchell S von Itzstein, David E Gerber, John D Minna
Elife|August 4, 2021
How lung cancer cells change identityMitchell S von Itzstein, Benjamin J Drapkin, John D Minna
Cancer Research|July 12, 2021
Contemporary Lung Cancer Screening and the Promise of Blood-Based BiomarkersMitchell S von Itzstein, David E Gerber, John D Minna
Vaccine|August 30, 2018
Strategies to maximize influenza vaccine impact in older adultsJennifer A Whitaker, Mitchell S von Itzstein, Gregory A Poland
JTO Clinical and Research Reports|March 17, 2022
Systemic and Intracranial Efficacy of Osimertinib in <i>EGFR</i> L747P-Mutant NSCLC: Case ReportDavid E Gerber, Melissa Mayer, Jeffrey Gagan, et al.
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Clinical Chemistry|February 28, 2024
Resistance Mechanisms in ROS1-Positive Lung Cancer: New Insight into a Rare but Clinically Important EntityMitchell S von Itzstein, David E Gerber
Translational Lung Cancer Research|March 11, 2026
A new therapeutic approach to <i>KRAS</i> mutant non-small cell lung cancer: the emerging role of exportin 1 inhibitionMitchell S von Itzstein, David E Gerber
Clinical Chemistry|May 5, 2020
Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and DiagnosisMitchell S von Itzstein, Shaheen Khan, David E Gerber
Ebiomedicine|September 25, 2020
Do mRNA profiles of lung adenocarcinomas provide information that will help individual patients?Mitchell S von Itzstein, David E Gerber, John D Minna
Journal of Medical Case Reports|July 24, 2022
Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case reportAmrit S Gonugunta, Mitchell S von Itzstein, David E Gerber
Translational Lung Cancer Research|September 12, 2022
Circulating mitochondrial DNA as a biomarker for lung cancer screeningMitchell S von Itzstein, David E Gerber, John D Minna
Elife|August 4, 2021
How lung cancer cells change identityMitchell S von Itzstein, Benjamin J Drapkin, John D Minna
Cancer Research|July 12, 2021
Contemporary Lung Cancer Screening and the Promise of Blood-Based BiomarkersMitchell S von Itzstein, David E Gerber, John D Minna
Vaccine|August 30, 2018
Strategies to maximize influenza vaccine impact in older adultsJennifer A Whitaker, Mitchell S von Itzstein, Gregory A Poland
JTO Clinical and Research Reports|March 17, 2022
Systemic and Intracranial Efficacy of Osimertinib in <i>EGFR</i> L747P-Mutant NSCLC: Case ReportDavid E Gerber, Melissa Mayer, Jeffrey Gagan, et al.
Pageof 6